1Q Revenues: $566.6 million (+67%)
1Q Earnings: $159.4 million (+94%)
Comments: Solaris sales were $566.6 million, up 67%, which included $87.8 million in reimbursements of prior year shipments related to an agreement with the French government. Sales also include additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). R&D expenses were $191.5 million, up from $74.5 in 1Q13.